全文获取类型
收费全文 | 2501篇 |
免费 | 188篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 170篇 |
妇产科学 | 44篇 |
基础医学 | 264篇 |
口腔科学 | 83篇 |
临床医学 | 247篇 |
内科学 | 467篇 |
皮肤病学 | 38篇 |
神经病学 | 117篇 |
特种医学 | 495篇 |
外科学 | 251篇 |
综合类 | 50篇 |
预防医学 | 113篇 |
眼科学 | 67篇 |
药学 | 132篇 |
中国医学 | 5篇 |
肿瘤学 | 161篇 |
出版年
2022年 | 11篇 |
2021年 | 23篇 |
2020年 | 11篇 |
2019年 | 15篇 |
2018年 | 38篇 |
2017年 | 17篇 |
2016年 | 28篇 |
2015年 | 37篇 |
2014年 | 43篇 |
2013年 | 82篇 |
2012年 | 67篇 |
2011年 | 77篇 |
2010年 | 100篇 |
2009年 | 83篇 |
2008年 | 84篇 |
2007年 | 55篇 |
2006年 | 63篇 |
2005年 | 67篇 |
2004年 | 53篇 |
2003年 | 53篇 |
2002年 | 58篇 |
2001年 | 25篇 |
2000年 | 38篇 |
1999年 | 42篇 |
1998年 | 143篇 |
1997年 | 129篇 |
1996年 | 135篇 |
1995年 | 107篇 |
1994年 | 80篇 |
1993年 | 88篇 |
1992年 | 33篇 |
1991年 | 33篇 |
1990年 | 36篇 |
1989年 | 67篇 |
1988年 | 54篇 |
1987年 | 75篇 |
1986年 | 57篇 |
1985年 | 54篇 |
1984年 | 33篇 |
1983年 | 41篇 |
1982年 | 48篇 |
1981年 | 30篇 |
1980年 | 48篇 |
1979年 | 25篇 |
1978年 | 20篇 |
1977年 | 33篇 |
1976年 | 39篇 |
1975年 | 32篇 |
1974年 | 9篇 |
1967年 | 8篇 |
排序方式: 共有2712条查询结果,搜索用时 15 毫秒
91.
目的了解河北省儿童医院住院患儿EB病毒(EBV)感染的流行病学特征,为儿童EBV感染的诊断和预防提供科学依据。方法收集2017年1—12月河北省儿童医院0~14岁EBV感染住院患儿的全血样本,采用酶联免疫吸附试验(ELISA)检测其EBV衣壳抗原(VCA)IgG及IgM抗体,抗早期抗原(EA)IgG抗体和抗核抗原1(NA1)IgG抗体,以检测结果为研究样本的抗体谱。根据4种EBV抗体的检测结果分为现症感染(抗VCA-IgM抗体阳性,抗NA1-IgG抗体阴性、抗VCA-IgG抗体、抗EA-IgG抗体阳性或阴性)、亚急性感染(抗VCA-IgG抗体阳性,抗VCA-IgM抗体、抗NA1-IgG抗体、抗EA-IgG抗体阳性或阴性)、既往感染(抗NA1-IgG抗体阳性,抗VCA-IgG抗体阳性或阴性,其他抗体均为阴性)和未感染(4种抗体均阴性)。按照患儿年龄、检出月份和性别分析各组的阳性率。结果共纳入符合要求的样本4 451例,其中3 257例(73.17%)抗体谱提示EBV感染,包括现症感染380例(8.54%)、亚急性感染616例(13.84%)、既往感染2 261例(50.80%)。不同年龄组原发阳性检出率差异有统计学意义(P<0.05),其中学龄前(>3岁)组的阳性检出率最高(P<0.05);不同检出月份组阳性检出率差异有统计学意义(P<0.05),7月份阳性检出率高于其他月份(P<0.05);男性患儿与女性患儿EBV感染率差异无统计学意义(P>0.05)。380例现症感染患儿的疾病谱以血液系统疾病[传染性单核细胞增多症、急性粒细胞缺乏症、血小板减少性紫癜、EBV相关嗜血细胞综合征]为主,其中传染性单核细胞增多症为临床常见疾病;其次是呼吸系统疾病(急性支气管炎、疱疹性咽峡炎、急性扁桃体炎);其他疾病谱包括神经系统疾病及血流感染、肾病综合征、川崎病。结论河北省儿童医院住院患儿EBV阳性检出率有年龄和检出月份差异,现症感染以血液系统疾病患儿为主,医院应根据流学病学特征制定相应预防措施。 相似文献
92.
93.
HUBERT COCHET M.D. YUKI KOMATSU M.D. FREDERIC SACHER M.D. AMIR SHERWAN JADIDI M.D. DANIEL SCHERR M.D. MATTHIEU RIFFAUD M.D. NICOLAS DERVAL M.D. ASHOK SHAH M.D. LAURENT ROTEN M.D PATRIZIO PASCALE M.D. JATIN RELAN Ph.D. MAXIME SERMESANT Ph.D. NICHOLAS AYACHE Ph.D. MICHEL MONTAUDON M.D. Ph.D. FRANÇOIS LAURENT M.D. MÉLÈZE HOCINI M.D. MICHEL HAÏSSAGUERRE M.D. PIERRE JAÏS M.D. Ph.D . 《Journal of cardiovascular electrophysiology》2013,24(4):419-426
MDCT/MRI Fusion for the Guidance of VT Ablation . Background: Delayed enhancement (DE) MRI can assess the fibrotic substrate of scar‐related VT. MDCT has the advantage of inframillimetric spatial resolution and better 3D reconstructions. We sought to evaluate the feasibility and usefulness of integrating merged MDCT/MRI data in 3D‐mapping systems for structure–function assessment and multimodal guidance of VT mapping and ablation. Methods: Nine patients, including 3 ischemic cardiomyopathy (ICM), 3 nonischemic cardiomyopathy (NICM), 2 myocarditis, and 1 redo procedure for idiopathic VT, underwent MRI and MDCT before VT ablation. Merged MRI/MDCT data were integrated in 3D‐mapping systems and registered to high‐density endocardial and epicardial maps. Low‐voltage areas (<1.5 mV) and local abnormal ventricular activities (LAVA) during sinus rhythm were correlated to DE at MRI, and wall‐thinning (WT) at MDCT. Results: Endocardium and epicardium were mapped with 391 ± 388 and 1098 ± 734 points per map, respectively. Registration of MDCT allowed visualization of coronary arteries during epicardial mapping/ablation. In the idiopathic patient, integration of MRI data identified previously ablated regions. In ICM patients, both DE at MRI and WT at MDCT matched areas of low voltage (overlap 94 ± 6% and 79 ± 5%, respectively). In NICM patients, wall‐thinning areas matched areas of low voltage (overlap 63 ± 21%). In patients with myocarditis, subepicardial DE matched areas of epicardial low voltage (overlap 92 ± 12%). A total number of 266 LAVA sites were found in 7/9 patients. All LAVA sites were associated to structural substrate at imaging (90% inside, 100% within 18 mm). Conclusion: The integration of merged MDCT and DEMRI data is feasible and allows combining substrate assessment with high‐spatial resolution to better define structure–function relationship in scar‐related VT. (J Cardiovasc Electrophysiol, Vol. 24, pp. 419‐426, April 2013) 相似文献
94.
Barbara Uhl Katharina T Prochazka Karoline Fechter Katrin Pansy Hildegard T Greinix Peter Neumeister Alexander JA Deutsch 《World journal of gastrointestinal oncology》2022,14(1):153-162
Approximately 8% of all non-Hodgkin lymphomas are extranodal marginal zone B cell lymphomas of mucosa-associated lymphoid tissue (MALT), also known as MALT lymphomas. These arise at a wide range of different extranodal sites, with most cases affecting the stomach, the lung, the ocular adnexa and the thyroid. The small intestine is involved in a lower percentage of cases. Lymphoma growth in the early stages is associated with long-lasting chronic inflammation provoked by bacterial infections (e.g., Helicobacter pylori or Chlamydia psittaci infections) or autoimmune conditions (e.g., Sjögren’s syndrome or Hashimoto thyroiditis). While these inflammatory processes trigger lymphoma cell proliferation and/or survival, they also shape the microenvironment. Thus, activated immune cells are actively recruited to the lymphoma, resulting in either direct lymphoma cell stimulation via surface receptor interactions and/or indirect lymphoma cell stimulation via secretion of soluble factors like cytokines. In addition, chronic inflammatory conditions cause the acquisition of genetic alterations resulting in autonomous lymphoma cell growth. Recently, novel agents targeting the microenvironment have been developed and clinically tested in MALT lymphomas as well as other lymphoid malignancies. In this review, we aim to describe the composition of the microenvironment of MALT lymphoma, the interaction of activated immune cells with lymphoma cells and novel therapeutic approaches in MALT lymphomas using immunomodulatory and/or microenvironment-targeting agents. 相似文献
95.
96.
97.
98.
When and how often a clinical trial is analyzed is as important as the use of appropriate methodology. Premature analysis may result in inaccurate estimation of tumor response and adverse effects as well as misrepresentation of survival. Moreover, bias may be introduced or the study may be abandoned entirely. Of parallel importance to the timing is the emphasis given to the analyses. If a randomized comparative trial of two regimens is conducted and a significant therapeutic effect is not discerned, the study is generally classified as a negative study. This view is oversimplified; the negative conclusion drawn must have a much more limited scope than is generally appreciated. Lastly, the pitfalls of interpreting time variable curves such as survival are of special note. Quite often the "tails" of the curves totally belie the true implications of the analysis. 相似文献
99.
100.
Dios Castro E Maquet Dusart JA 《Archivos de la Sociedad Espa?ola de Oftalmología》2000,75(11):775-778
PURPOSE/METHOD: We present a case of a patient who developed recurrent epithelial herpes simplex keratitis after starting treatment with latanoprost. Her ophthalmic history was only remarkable for a past episode of herpetic keratitis 21 years previously. RESULTS/CONCLUSIONS: Episodes of herpetic keratitis were under remission only when latanoprost was discontinued. No recurrences of herpes simplex keratitis have been observed since then. Latanoprost usage might be associated with recurrent episodes of herpes simplex keratitis in patients with previous history of ocular herpes simplex virus infection. 相似文献